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Selective cyclooxigenase (COX)-2 inhibitors were developed to prevent Traditional Non-Steroidal 
Anti-Inflammatory DrugS (tNSAIDs) gastro-intestinal adverse effects. VA692, a recently disclosed 
selective COX-2 inhibitor, structurally related to well-known marketed coxibs, showed anti-
inflammatory, and anti-nociceptive properties.  
The aim of this study was to analyze the anti-inflammatory effect of VA692, in comparison with 
celecoxib. For this purpose we evaluated pro-inflammatory cytokines and anti-oxidant enzymes 
gene expression, apoptosis and ROS production, and PGE2 release in chondrocytes (both primary 
cultures and immortalized cell line T/C-28a2) treated with the two drugs. Furthermore, a proteomic 
analysis has been performed in T/C-28a2 cell line to evaluate modifications in their proteomic 
profile following drug treatment in presence of IL-1β.  
Our results demonstrated the anti-inflammatory effect of the novel synthesized VA692, and 
confirmed those of celecoxib, in counteracting the stimulus of IL-1β in both osteoarthritic (OA) 
chondrocytes and T/C-28a2 cell line. Furthermore, the data underlined the possible anti-apoptotic 
and anti-oxidant role of VA692, implying its regulation in superoxide anion production as indicated 
by the modulation of anti-oxidant enzymes. 
The proteomic analysis provides new information about the effect of VA692 on human T/C-28a2 
intracellular proteome, demonstrating the usefulness of this approach in the identification and 
quantifications of several proteins. Modulation of some proteins such as Hsp90 and SOD by VA692 
could explain its role in the therapeutic approach of OA. 
Based on our results, we can affirm that VA692 has more beneficial effect compared with celecoxib 
particularly regarding the modulation of oxidant/anti-oxidant system and proteome profile of human 
articular chondrocytes. 





Osteoarthritis (OA) is the most common rheumatic disease affecting middle aged and older people 
worldwide and it is the main cause of disability and impairment in adults [1]. The disorder is 
characterized by progressive destruction of cartilage and subochondral bone remodeling 
accompanied by synovial inflammation and loss of normal joint function [2].  
The international guidelines for the treatment of OA include non-pharmacological and 
pharmacological approaches. The pharmacological management actually available is represented by 
acetaminophen, traditional non-steroidal anti-inflammatory drugs (tNSAIDs), analgesics, opioids 
and duloxetine (a serotonin and norepinephrine reuptake inhibitor with central nervous activity), 
which provide only symptomatic relief [3,4]. 
The clinical efficacy of tNSAIDs is related to their ability in modulating pain and inflammation 
impairing prostaglandin E2 (PGE2) release by means of the inhibition of cyclooxygenase 2 (COX-
2) activity [5]. However, gastrointestinal and renal adverse effects of tNSAIDs due to their 
inhibition of the constitutive cytoprotective COX-1 is well established [6,7], even if this concept 
was recently challenged by the detection of constitutive COX-2 activity in several tissues and 
organs, including the kidney and brain [8]. 
In addition, the possible negative effect of tNSAIDs on cartilage metabolism, in particular in long 
term treatment, was documented [5]. However, data about their effects on articular cartilage are not 
consistent; in fact, some reports evidence the involvement of these drugs in cartilage destruction, 
while, in other studies, their chondroprotective action was observed [9-11].  
Selective COX-2 inhibitors belongs to the class of diaryl heterocycles compounds, also referred to 
as coxibs [12]. These drugs specifically act on COX-2, with similar efficacy and less toxicity 
[13,14], and have been developed to prevent common adverse effect associated to tNSAIDs. Along 
with beneficial anti-inflammatory activity of celecoxib, the prototype of coxibs, many in vitro 
studies reported its positive effect on cartilage damage during OA [15-17]. Unfortunately, an 
increased risk for cardiovascular events has been associated with chronic use of tNSAIDs and 
 
 
coxibs [18,19]. The discovery of certain variability in individual reactions to these drugs, mainly 
due to patient’s genetic background [20] and the need of potentially safer drugs for the successful 
management of OA, promoted strategies of design and synthesis of new class of pyrrole-containing 
antiflogistic/analgesics agents as selective COX-2 inhibitors, structurally related to the main coxibs 
[21,22].  
Within a large program aimed at the discovery of new anti-inflammatory agents based on the 1,5-
diarylpyrrole scaffold, a series of substituted 1,5-diarylpyrrole-3-alkoxyethyl ethers endowed with a 
relevant anti-inflammatory and anti-nociceptive properties was disclosed [23]. The manipulation of 
3-alkoxyethyl chain of above-cited compounds allowed some of us to obtain 1,5-diarylpyrrole-3-
nitrooxyethyl derivative VA694, a hitherto unknown COX-inhibiting nitric oxide (NO) donor 
offering an improved safety profile having a dual mechanism of action involving COX-2 inhibition 
and NO release (Figure 1). This molecule resulted to be very active, being endowed with high 
selective COX-2 inhibitory properties, highlighting its anti-inflammatory and antinociceptive 
activity [24], associated with chondroprotective effects when tested on human chondrocytes [25]. 
Along with VA694 it appeared interesting to deepen the pharmacological behaviour of its 
metabolite, resulting from the metabolic conversion of nitrooxyalkyl ether VA694 into the 
corresponding hydroxyethyl derivative VA692 which, after NO release, still retained a very 
promising selective COX-2 inhibition, showing appreciable anti-inflammatory and anti-nociceptive 
activity in animal model of inflammation [24]. On the basis of these findings VA692, underwent 
biological assays performed on bovine articular cartilage, showing chondroprotective effects being 
able to inhibit glycosaminoglycans release induced by Interleukin (IL)-1β [24]. 
So, the aim of this study was to analyze the anti-inflammatory effect of the novel selective COX-2 
inhibitor, VA692, in comparison with celecoxib, as the reference compound, in both human 
chondrocyte cell line T/C-28a2 and in primary cultures of human articular OA chondrocytes 
(HAC). All the experiments were performed in the presence of IL-1β. By means of the isobaric tags 
for relative and absolute quantitation (iTRAQ) methodology, our goal was to identify the profile of 
 
 
proteins produced by our chondrocyte cultures, and to quantitatively analyze the different expressed 
profiles after the treatment with the drugs of interest in presence of IL-1β. This allows us to better 
understand and characterize the possible mechanism of action of celecoxib and VA692. 
2. Material and Methods 
2.1 Culture of chondrocytes 
Human T/C-28a2, kindly provided by Glodring laboratory, was derived from human juvenile costal 
cartilage generated through a transfection with retroviral vector pZipNeoSV (X) containing the 
SV40 large T antigen as previously described [26]. These immortalized human chondrocytes can be 
manipulated in culture, displaying cartilage-specific modulation by inflammatory mediators, so they 
can be used as a model for studying normal and pathological mechanisms, allowing investigations 
in a largely unlimited and standardized way [26]. 
Human articular cartilage was obtained from the femoral heads of five OA patients undergoing hip 
replacement surgery [27,28] in the Orthopaedic Department at University Hospital of A Coruña, 
Spain and at University Hospital of Siena, Italy. The study was approved by the Ethic Committee of 
Clinical Investigation of Galicia and by the Ethics Committee of the Azienda Ospedaliera 
Universitaria Senese. The sex distribution of patients was two males and three females with a mean 
age of 68 years (range 66-72). 
The chondrocytes were isolated after surgery. Briefly, cartilage sections were aseptically removed 
from each donor and enzymatically digested with trypsin (Sigma-Aldrich) for 15 minutes (min) at 
37˚C and then with type IV collagenase (Sigma-Aldrich) for 12–16 hours (h) at 37°C. Chondrocytes 
were recovered, seeded into 10-cm diameter tissue culture plates and maintained in a 5% CO2 and 
90% humidified atmosphere at 37ºC until 80% confluence was reached. Cells were grown in 
Dulbecco´s Modified Eagle Medium (DMEM) (Gibco), containing 10% Fetal Bovine Serum (FBS) 
(Gibco), with 200 U/mL penicillin and 200µg/mL streptomycin (P/S) (Gibco). OA primary 




2.2 Pharmacological treatment of the cell cultures 
The effects of our compound VA692 and celecoxib (kindly supplied by Rottapharm Biotech, Italy) 
were analyzed in the presence of IL-1β (5 ng/ml) (Sigma) after 2 h of pre-treatment with the 
compounds. All the experiments were carried out during 48 h after cells treatments in DMEM with 
0% FBS. 
The drugs were dissolved in dimethyl sulfoxide (DMSO) (Sigma) and then further diluted in the 
culture medium to obtain the final concentration required. The concentration of DMSO in the 
medium during the treatment did not exceed 0.1% neither affecting cell growth nor its well known 
anti-oxidant activity [29]. 
2.3 Experimental procedures 
2.3.1 RNA isolation and gene expression  
Total RNA from cells was extracted using Trizol® Reagent (Thermo Fisher Scientific) following 
the manufacture’s procedures. Afterwards, 1μg of total RNA was reverse transcribed using NZY 
First-Strand cDNA Kit (NZY Tech Genes and Enzymes, Portugal) according to manufacturer's 
instructions. 
Quantitative real-time PCR (qRT-PCR) reactions were performed in LightCycler 480 II instrument 
(Roche Molecular Biochemicals) using TaqMan Universal Master Mix (Applied Biosystems) 
Analysis of the results was carried out using Qbase+ version 2.5 software (Biogazelle, Gent, 
Belgium) using ∆∆ Ct method. Normalization was carried out considering as reference 
housekeeping gene ribosomal protein L13a (RPL13A). This gene was chosen by software geNorm 
version 3.5 (Primer design, Southampton University's School of Medicine, United Kingdom), an 
algorithm able to evaluate the most stable housekeeping gene derived from a group of tested 
candidate reference genes. The software determines the gene expression stability measure for a 
reference gene calculating the average pairwise variation of that gene in comparison to all other 
tested genes. Stepwise exclusion of the gene with the highest stability measure value allows to 
calculate the tested genes according to their expression stability [30]. Sequence of primers and 
 
 
probes are listed in Table 1. 
2.3.2 PGE2 release 
PGE2 levels were evaluated in the conditioned media and determined through competitive PGE2 
EIA -Monoclonal kit from Cayman Chemical Co. (Ann Arbor, MI, USA) according to the 
supplier’s instructions. Sensitivity of the assay was 15 pg/ml. Inter-assay and Intra-assay 
coefficients of variation were 12.4-35 % and 4.2-30.4 %, respectively. 
2.3.3 Detection of apoptotic cells 
Detection of apoptotic cells were developed using Annexin V-FITC and propidium iodide 
(Immunostep). T/C-28a2 cell line and OA chondrocyte cultures were plated in 12-well plates (8x10
4
 
cells per well) during 24 hours in DMEM with FBS 10%. Then, the medium was discarded and the 
cells were cultured in DMEM with FBS 0.5% normally used for the treatment (n=3). Afterwards, 
the cells were washed and harvested with trypsin, collected into cytometry tubes and centrifuged for 
10 minutes at 1500 rpm. The supernatant was discarded and the pellet resuspended in 1 X annexin 
binding buffer followed by 5 μl of Annexin V-FITC and 5 μl of propidium iodide (PI) addition to 
each cell suspension and incubated at room temperature for 15 min in darkness. After incubation, 
400 μl of 1x Annexin-binding buffer was added prior to flow cytometry analysis. A total of 1x10
4
 
cells per assay were measured. Data were analyzed with Cell Quest software (Becton Dickinson). 
The evaluation of apoptosis was performed considering staining cells simultaneously with Annexin 
V-FITC and PI, allowing the discrimination of intact cells (Annexin V-FITC and PI negative), early 
apoptotic state (Annexin V-FITC positive and PI negative) and late apoptosis state (Annexin V-
FITC and PI positives).  
Results were expressed as percentage of positive cells to each dye (total apoptosis) and represented 




2.3.4 Mitochondrial ROS production  
To evaluate mitochondrial superoxide anion (O2
-
) production the cells were incubated in Hank´s 
Balanced Salt Solution (HBSS) (Sigma) with 5 µM of MitoSOX
TM
 Red (Thermo Fisher Scientific), 
during 15 min at 37º C in darkness. Besides, cells were resuspended in saline solution prior to be 
analyzed by flow cytometry. A total of 1x10
4
 cells per assay were measured by flow cytometry and 
data were analyzed with CellQuest software (Becton Dickinson). Results were collected as median 
of fluorescence (AU) and represented the mean of three independent experiments (mean ± SD). 
Total protein extraction and western blot analysis 
3x10
5
 T/C-28a2 cells were plated onto 6-multi plates during 24 hours in DMEM without phenol red 
(Gibco, Thermo Fisher Scientific) with FBS 10%. Then, the medium was discarded, and the cells 
were cultured in DMEM with FBS 0.5% normally used for the treatment. After the treatment, the 
cells were lysed using 100μl of lysis buffer [0.2 M Tris-HCl pH 6.8, sodium dodecyl sulphate 
(SDS) 2%, Glycerol 20%] with additional inhibitors to prevent degradation of the samples (PMSF 
0.1M and protease inhibitor cocktail (Sigma)). The concentration, purity and integrity of proteins 
were evaluated by measuring the OD at 260 nm and the 260/280 using NanoDrop ND1000. 20µg of 
protein for each sample were loaded and resolved using 10% SDS-polyacrylamide electrophoresis 
gel (SDS-PAGE) (Power Pac TM HC, Bio-Rad). Proteins were then transferred to nitrocellulose 
membrane (Trans-Blot SD, BioRad) and, after blocking, the membrane was incubated with the 
purified mouse monoclonal antibody for SOD2 detection (BD Biosciences Transduction 
Laboratories TM) (1:1000). Finally, immunoreactive bands were detected by chemiluminescence 
using the appropriated horseradish peroxidase (HRP) conjugate secondary antibodies and enhanced 
chemiluminescence detection reagent (Luminata
TM
 Western HRP Chemiluminescence Substrates) 
(Millipore). Images of the bands were digitized using LAS-3000 Image Reader (Bio-Rad) and 
quantitative changes in band intensities were analyzed by Image Quant 5.2 software (GE 
Healthcare). To assure the evaluation of an equal amounts of the total proteins, membrane was also 
 
 
hybridized with monoclonal human anti- β-tubulin antibody, used as control. Results were 
normalized with the loading control β-tubulin. 
2.3.5.1 Protein digestion and iTRAQ labeling 
The cells were collected, lysed with urea 6 M and thiourea 2 M and cleaned up by acetone 
precipitation. Protein pellets were dried at air and then resuspended in 30μl of Dissolution Buffer 
(0.5 M triethylammonium bicarbonate at pH 8.5) (AB Sciex, Foster City, CA, USA). Protein 
concentration was determined by using NanoDrop ND1000 (Thermo Scientific). Then, 50 µg of 
proteins from each condition were reduced, alkylated, and digested with trypsin. Then iTRAQ 
labeling was performed according to the supplier's instructions (ABSciex, Foster City, CA, USA). 
The samples were labeled as follows: 113 (basal condition), 114 (IL-1β), 115 (Cel 1µM + IL-1β), 
116 (VA692 1µM + IL-1β), 117 (basal condition), 118 (IL-1β), 119 (Cel 1µM + IL-1β), 121 
(VA692 1µM + IL-1β). iTRAQ-labeled peptides were mixed and desalted using reversed phase 
columns (Pierce C18 Spin Columns, Thermo Fisher Scientific, Rockford, IL, USA) prior to liquid 
chromatography coupled to mass spectrometry (LC-MS) analysis. 
2.3.5.2 Liquid Chromatography (LC) 
The peptides mixture was separated by off-line reversed phase (RP) -LC at basic pH (pH 10) to 
lower its complexity. Labeled peptides were resuspended in 150 μL of buffer A (10mM ammonium 
hydroxide, 5% acetonitrile), 140 μL were injected into an HP 1200 system (Agilent Technologies, 
Santa Clara, CA, USA) and the separation was performed on a C18 reversed-phase column (Zorbax 
extend C18, 100 × 2.1 mm id, 3.5 μm, 300Å; Agilent), at a flow rate of 0.2 mL/min. The 
chromatogram was detected using a UV detector at 214nm. Several fractions were pooled post-
collection (FC203B fraction collector, Gilson, Middleton, WI, USA) based on the peak intensity of 
the UV trace, yielding a total of 16 samples per LC run. Each fraction was dried in a vacuum 
concentrator and stored at -20°C for the next step of analysis. For a second separation, the dried 
peptide fractions were dissolved in 0.1% trifluoroacetic acid (TFA) and 2% acetonitrile. Then, 5µL 
 
 
of the sample were injected into a capillary trap column (0.5×2 mm, Michrom Bioresources, 
Auburn, CA, USA) at a flow rate of 15 µL/min. Peptides were desalted for 10 minutes and loaded in 
a C18 column (Integrafit C18, Proteopep II, 75µm id, 10.2 cm, 5µm, 300 Å; New Objective), at a 
constant flow rate of 350 nl/min, to carry out the separation using linearly increasing concentration 
of acetonitrile in buffer B. The RP fractions were collected and mixed with matrix a-cyano-4-
hydroxycinnamic acid (Sigma-Aldrich) at 3 mg/mL in 0.1% TFA in 70% acetonitrile at a flow rate 
of 1.2 µL/min, using the Sun Collect MALDI Spotter/Micro Collector (SunChrom 
Wissenschaftliche Gerate GmbH, Germany). Fractions, collected each 15 seconds, were then 
spotted onto a MALDI plate for MS analysis. 
2.3.5.3 MS/MS analysis 
Data acquisition was accomplished in a positive ion mode using a 4800 analyzer equipped with 
TOF/TOF ion optics (ABSciex) and 4000 Series Explorer software version 3.5.1 (ABSciex). MS 
spectra from m/z 800-4000 were acquired for each fraction using 1500 laser shots processed with 
internal calibration. After screening of LC-MALDI sample positions in MS positive reflector mode, 
the fragmentation of automatically selected precursors was performed at a collision energy of 1 kV 
with CID gas (air). Up to 25 of the most intense ion signals per spot position with signal/noise ratio 
(S/N) above 80 were selected as precursors for MS/MS acquisition. The number of shots was 2000 
for MS/MS, the laser intensity was set to 4700. A second MS/MS was acquired excluding the 
precursors selected in the previous MS/MS run. Precursors with S/N>30 were selected to identify 
proteins that were not identified in the previous run. 
2.3.5.4 MS data analysis 
Protein identification was carried out by Protein Pilot
TM
 software version 4.5 (ABSciex). The 
Paragon algorithm in the software needed as the default search program with trypsin as the 
digestion agent and MMTS as a fixed modification of cysteine. Biological modifications were 
programmed in the algorithm. Each MS/MS spectrum was researched in the Uniprot/Swissprot 
 
 
database for Homo sapiens. The identity of the protein from the analyzed peptide was confirmed 
and the ratio of the peak are of iTRAQ reporter ions were used to compare the abundance of the 
protein found in the sample. Only proteins identified with at least 95% of confidence, or a Prot 
Score (protein confidence measure) of at least 1.3 were reported. Data were normalized for loading 
error by bias and the background correction was calculated through Pro Group
TM 
algorithm 
(ABSciex). To determine the cut-off value for significant fold changes, coefficient of variation and 
cumulative frequency were calculated for the common proteins employing the R statistical package. 
The results obtained from Protein Pilot were exported to Microsoft Excel for other analyses. 
2.3.6 Statistical analysis 
Proteomics data were analyzed employing normalization tools and statistical package from 
ProteinPilot. The results obtained were exported to Microsoft Excel for further analyses. Three 
independent experiments were performed and the results were expressed as the mean±SD of 
triplicate values for each experiment. Data normal distribution was confirmed by Shapiro-Wilk, 
D’Agostino & Pearson e Kolmogorov-Smirnov tests. Quantitative real-time PCR data were 
evaluated by Kruskal-Wallis test with Dunn's multiple comparison test using 2
-ΔΔC
T values for each 
sample. Flow cytometry results were analyzed by ANOVA with Bonferroni post-hoc test.  All 
analyses were performed using the SAS System (SAS Institute Inc., Cary, NC, USA) and GraphPad 
Prism 6.1. A significant effect was indicated by a p-value<0.05. 
3. Results 
3.1 Anti-inflammatory capacity of celecoxib and VA692 
The chondrocytes (T/C28-a2 and HAC) were stimulated with IL-1β to induce an inflammatory 
response, this status was confirmed by a significant up-regulation expression level of all genes 
analysed and a significant PGE2 release levels in comparison with the basal condition. 
A significantly inhibition of the gene expression of the inflammatory indicators evaluated (COX-2, 
IL-1β, IL-6 and IL-8) was observed with celecoxib or with the new compound VA692 at the 
 
 
concentration of 1 µM (Figure 2A,B). In the case of VA692 the inhibition of 4 gene expression 
were obtained also at low concentrations evaluated (data not shown) and this results was more 
significant in the case of chondrocytes from OA patients than in the chondrocytes from cell line.  
Another analysis developed to evaluate the possible anti-inflammatory response in the chondrocytes 
after drug treatment was the detection of PGE2 release. Celecoxib significantly inhibited PGE2 
release induced by IL-1β in both cell types (Figure 2C). The new compound VA692 showed the 
same effect over the both type of cells analyzed, reflecting a significant decreased in the PGE2 
levels, up to basal concentration (Figure 2C). 
3.2 The effect of the compounds over the oxidant/anti-oxidant system and apoptosis detection 
The assessment of mitochondrial ROS production, estimated by the measurement of anion 
superoxide by flow cytometry, showed that IL-1β increased significant the levels of O2
- 
in 
comparison with basal condition. The cell treatment with either celecoxib or VA692 at 1µM had the 
capacity to counteract the negative effect of IL-1β in T/C-28a2 cell line and in HACs reducing the 
levels of O2
-
 up to basal condition (Figure 3A).  
As shown in Figure 3B and C, the gene expression of two detoxification enzymes (SOD-2 and 
CAT) was analysed after stimulation with IL-1β and treatment with celecoxib and VA962. Il-1β 
provoked a strong increase of mRNA levels of both enzymes in both cell types. After 
pharmacological treatments, a statistical significant decrease was observed in comparison with Il-1β 
condition in chondrocytes from cell line and primary culture. The reducing effect was similar for 
both drugs in HACs while in T/C-28a2 was higher for the new compound VA692 (Figure 3B,C). 
Western blot was developed to complete the study of drugs effect over the mitochondrial ROS 
production (Figure3D). The densitometry quantification showed significantly higher SOD-2 protein 
levels after stimulation with IL-1β, in comparison to basal conditions. A higher increase of SOD-2 
protein levels was observed after treatment with celecoxib, and VA692. The percentage of apoptotic 
cells after pharmacological treatment was also evaluated. As shown in figure 3E, flow cytometry 
data showed that the stimulation with IL-1β significantly increased the ratio of apoptosis (the ratio 
 
 
of apoptosis was referenced to basal condition) in T/C-28a2 cell line (130% increase) and in HACs 
(50% increase). The treatment with celecoxib or VA692 was able to restore the ratio of apoptosis up 
to basal condition in T/C-28A2 and in less extent in HACs, being in this case statistically significant 
only for celecoxib. 
3.3 Proteomic profiling of celecoxib or VA692 IL-1β-treated cell cultures 
A total of 797 proteins have been identified with at least two distinct peptides (95% of confidence) 
and a protein pilot total score ≥ 2 after combining the results from all the experiments (false 
discovery rate kept at 1%) (Supplementary Table S1). As expected, the most abundant proteins in 
all the conditions were cytoskeletal proteins. In particular, intermediate filament protein vimentin 
(VIME), filamins (FLNA, FLNB, FLNC), alpha actinin- (ACTN1), or proteins involved in calcium 
metabolism such as calreticulin (CALR) and calumenin (CALU) have been identified. Proteins 
involved in synthesis and maturation of ribosomes, such as nucleophosmin (NPM) and nucleolin 
(NUCL), as well as in osteoablast differentiation, clathrin heavy chain 1 (CLH1) and fatty acid 
synthase (FASN), were also identified. A gene ontology (GO) enrichment analysis was performed 
on this set of proteins and the Pike tool was used to assign the involved biological processes and the 
cellular compartment distribution of the identified proteins (35). Bioinformatic analysis 
demonstrated the involvement of these proteins in several cellular (32%) and metabolic (26%) 
processes, in particular regulating cell cycle (cytoskeletal proteins) and cell communication (signal 
transduction molecules) (Figure 4A). As described in figure 4B, 95% of the identified proteins were 
associated to the intracellular compartment; 46% of them were located inside the cytoplasm, 15% 
inside the cytoskeleton, 13% inside the nucleous, or located in other subcellular organelles such as 
endoplasmic reticulum (11%) and mitochondrion (6%).  
Proteomics analysis by iTRAQ labelling also enabled the relative quantification of the identified 
proteins. The iTRAQ ratios were calculated using the Protein Plot software, and subsequently the 
cut off value for significant fold changes was established at ≥ 1.5 (or ≤ 0.66) using statistic tools 
from R package. Afterwards, we found 34 proteins significantly modulated (p≤ 0.05) in IL-1β 
 
 
stimulated T/C-28a2 cells in comparison to basal conditions: 26 were up-regulated and 8 were 
down-regulated (Table 2). Only 7 proteins were significantly modulated by celecoxib treatment in 
comparison to basal conditions, 5 were up-regulated while 2 down-regulated (Table 3); on the other 
hand, VA692 was able to modulate, in a significant manner, 123 proteins, 70 of them were 
increased and 53 were decreased (Table 4). The Venn diagram represents the overlap of proteins 
altered in T/C-28a2 VA692 in presence of IL-1β and the IL-1β tested alone, highlighting the 
characteristic protein profile induced by each treatment; only 22 proteins were commonly 
modulated by the two treatments, indicating that 101 proteins were regulated by the only effect of 
VA692 in a specific manner (Figure 4C). Among them, proteins with structural function, chaperone 
and glycolitic enzymes resulted decreased after pharmacological treatment. In addition, STRING 
database was searched for protein interaction analyses to evaluate the effect of VA692 in 
combination with IL-1β. Figure 5A showed the interaction of the 53 down-regulated proteins with 
each other to constitute a network; some of them are involved in osteoblast differentiation (Figure 
5B). Figure 5C depicting the interaction of the 70 up-regulated proteins with each other to constitute 
a network; some of them are involved in protein translation (Figure 5D). 
4. Discussion 
The present study examines the in vitro anti-inflammatory effects of a new selective COX-2 
inhibitor, VA692, along with celecoxib as the reference compound. T/C-28a2 cell line was 
employed to perform all the preliminary analysis with different concentration of both drugs. Then, 
the optimal conditions were tested in primary chondrocytes to confirm the results. The 
concentrations of the drugs tested in our experiments were close to those found in vivo and 
comparable with the concentrations tested by other authors [15,23]. All the experiments were 
performed in presence of the cytokine IL-1β, generally used in in vitro models to mimic the 
circumstances driving to in vivo cartilage degradation [31,32].  
Previous results from in vitro tests have been performed to evaluate the inhibitory potency and 
 
 
selectivity of the title compounds, and reported very encouraging COX-2 inhibitory activity of 
VA692 (IC50 of 0.089 μM) (celecoxib, IC50 of 0.089 μM) [23]. Cosidering its very encouraging 
inhibitory activity, compound VA692 was submitted to additional pharmacological evaluations to 
assess its in vivo anti-inflammatory and anti-nociceptive activities. Firstly, an analysis on a 
chemical murine model of visceral pain, induced by an intraperitoneal injection of acetic acid, was 
performed; the evaluation of the number of abdominal constrictions induced by acetic acid proved 
the analgesic properties of VA692 compared to celecoxib [23]. Moreover, the effect of VA692 on 
pain threshold alteration and oedema reduction was observed, by the same authors, in rats injected 
with carrageenan; the compound was able to block the painful stimulus showing a good activity 
against carrageenan-induced hyperalgesia [23]. Finally, the efficacy of VA692 was also determined 
in a rat OA model induced by intra-articular knee injection of monoiodoacetate (MIA), able to 
induce chondrocytes necrosis, decrease in cartilage thickness and osteolysis. Repeated treatment 
with VA692 prevented monoiodoacetate hyperalgesia [23]. 
On the basis of these preliminary results, in the present study we tested the effect of VA692 also in 
human chondrocyte cultures in order to evaluate its possible modulation of cell metabolism.  
The results obtained in HAC stimulated with IL-1β, support the data from literature reporting a 
significant increase of IL-1β, IL-6, IL-8, as well as a large amount of PGE2 production, which is 
reasonable to be related to the increase of COX-2 gene expression [33]. On the other hand, this is 
the first study showing an up-regulation of these pro-inflammatory cytokines expression levels in 
T/C-28a2 cell line. de Boer et al [34] evaluated the effect of celecoxib in vivo in patients with knee 
OA. The authors observed the reduction in PGE2 levels in treated group compared to controls, 
indicating the ability of this compound in inhibiting COX-2 effect. In addition, in vitro and in vivo 
studies (in animal models of OA) demonstrated the anti-inflammatory effect of celecoxib, with 
respect to tNSAIDs, in counteracting the COX-2 and PGE2 production after the pro-inflammatory 
stimulus of IL-1β and TNF-α [16,35,36]. According to these studies, our data on primary cultures 
confirm the anti-inflammatory effect of celecoxib in reducing the expression of COX-2 and the 
 
 
release of PGE2 induced by IL-1β. In addition, the drug also caused a down-regulation in IL-6 and 
IL-8 expression levels, confirming the data by Sanchez et al. [37]. Furthermore, we demonstrated 
that the novel compound VA692 had a similar anti-inflammatory effect to celecoxib, showing a 
better modulation of IL-6, IL-8 and PGE2 in cell line model and in primary OA chondrocytes. 
Accumulating evidence indicates chondrocyte apoptosis as another important factor involved in the 
pathogenesis of OA. Apoptosis analysis performed in our research appeared in agreement with 
previous studies [38,39] showing a trend to increase of apoptosis percentage in OA chondrocytes 
stimulated  with IL-1β, even if not significant, principally attributed to experimental variability and 
at the low number of available samples; with regard to T/C-28a2 cell line, a significant increase of 
apoptotis in IL-1β-stimulated cells was observed. Our treatment demonstrated the ability of 
celecoxib in reducing, in a significant manner, the apoptosis ratio in human T/C-28a2 cell line after 
the negative stimulus of IL-1β, showing a trend also in counteracting the ratio of apoptosis in 
primary OA chondrocytes cultures, as previously described [40]. More interestingly, we underlined 
for the first time the anti-apoptotic effect of the new compound VA692, able to restore cell viability 
after stimulation with IL-1β in T/C-28a2 cell line. 
Under normal conditions, the production of endogenous ROS are balanced by the antioxidant 
defence system. In pathological circumstances as OA, when the cellular antioxidant ability is not 
sufficient to detoxify ROS, the oxidative radicals accumulation affects cellular membranes, nucleic 
acids and extracellular matrix components [41]. Chondrocytes from OA cartilage have significantly 
more ROS-induced DNA damage than in normal cartilage, mediated by IL-1β effect with an 
increase in their mitochondrial superoxide levels [42]. Our data appear in agreement with the 
current literature showing a trend of increase in mitochondrial superoxide anion production both in 
T/C-28a2 cell line and in OA chondrocytes cultures stimulated by IL-1β. 
A limited number of in vivo and in vitro studies have been performed regarding the effects of coxibs 
on oxidant/antioxidant activities [16,42,43], in particular with a lack of evidence about their effects 
on chondrocytes. An in vivo study of Ozgocmen et al [43] documented the effect of celecoxib in 
 
 
reducing NO levels in patients with knee OA; moreover, the inhibition of NO production, after IL-
1β stimulus, by celecoxib was observed in chondrocytes of ligament-damaged OA rat joints [16]. 
Our results seem to support this evidence reporting the inhibitory role of celecoxib in oxidant 
system, showing its effect in reducing the superoxide anion production in T/C-28a2 cell line. In 
addition, a more evident effect was observed after the treatment with the new compound VA692 in 
both cell culture models showing its ability to counteract the mitochondrial O2
-
 production induced 
by IL-1β. We also observed a significant increase of both SOD-2 and CAT mRNA expression 
levels in T/C-28a2 cell line and in OA chondrocyte following incubation with IL-1β. This led us to 
speculate about the raised levels of these detoxificant factors could be related to the increase of their 
activity as a consequence of increased ROS production after the cell incubation in presence of pro-
inflammatory cytokines essentials in the development of OA processes.  
Cimen et al [44] studied the effect of celecoxib, ibuprofen and meloxicam on free radical 
metabolism of erythrocytes in OA patients, reporting a significant decrease in SOD activity in 
patients treated with the drugs. More recently, it has been compared the effect, on free radical 
metabolism, of tenoxicam and celecoxib in serum levels of OA patients. Patients treated with 
celecoxib decreased their nitrite levels, while no changes in SOD activity were observed compared 
to baseline [43]. Our report confirm the effecacy of celecoxib in modulating SOD-2 and CAT and, 
more interestingly, showed the ability of the new compound VA692 in reducing antioxidant 
enzymes mRNA expression levels, in T/C-28a2 cell line and in OA chondrocytes cultures after 
stimulation with IL-1β. To summarize, we showed for the first time the role of VA692 in redox 
balance, demonstrating its effect in the reduction of both superoxide anion production and anti-
oxidant enzymes. 
Surprisingly, conversely to our SOD-2 mRNA result, its protein levels appeared increased after the 
treatment with the new molecule VA692 following our analysis carried out at western blot test in 
T/C-28a2 cell line. There is no evidence about an increase of its protein levels afterwards a drug 
treatment in this type of cell line. However, a recent in vitro pharmacoproteomic study performed in 
 
 
OA chondrocyte cultures appeared in agreement with our data reporting higher SOD-2 protein 
levels in that cells after treatment with chondroitin sulfate and IL-1β [45]. These obtained data 
might stimulate to deeper investigate the reasons why a discrepancy between mRNA expression and 
protein levels were observed after treatment with VA692, suggesting that some expressional 
changes can occur at protein level. One reason for this inconsistency may be related to a 
translational regulation, or, for instance, to the post-translational modification of proteins, as 
phosphorylation, glycosylation or methylation [46]. Further studies should be performed to confirm 
these possible explanations and to understand the implication of VA692 in this sense. 
For the global analysis of chondrocytes proteome, we performed a quantitative study using iTRAQ 
technique, in T/C-28a2 cells treated with celecoxib and VA692 in presence of IL-1β. To our 
knowledge, this is the first pharmacoproteomic study performed in T/C-28a2 cells. The experiment 
allowed us to create a quantitative profile of chondrocyte intracellular protein changes managed by 
our drugs of interest; moreover, the Venn analysis led us to discriminate the modulation of proteins 
related to a specific treatment performed, demonstrating the real impact of compound VA692 on 
T/C-28a2 proteome. On the basis of our results, celecoxib was able to modulate only 7 proteins in a 
significant manner. To date, only some in vitro experiments were performed in carcinoma cell lines 
and reported the antiproliferative and antitumor activities of celecoxib; these studies underlined a 
modulation of celecoxib of non-COX-2 protein targets involved in tumorigenesis [47-49]. These 
studies can not be compared with our results neither for the type of cells employed nor for the 
proteomic strategy used. More interesting and encouraging results were obtained testing compound 
VA692. The new drug modulated 123 proteins, 53 were down-regulated and 70 were up-regulated. 
Among the down-regulated proteins, some with structural function (VIM, ACTN1, VINC, FLN, 
COF) were identified. The architecture of cytoskeleton consists of a network of actin 
microfilaments, microtubules and vimentin intermade filaments and play significant roles in 
chondrocytes physiology, in particular in biomechanics and in mechanotransduction signaling [50]. 
Different studies reported altered vimentin levels in chondrocytes as a consequence of a particular 
 
 
stress or articular damage. Increased vimentin fragments were detected in OA rat model and in 
human cartilage from OA patients; this was correlated to a disruption in vimentin network [51,52]. 
High abundance of vimentin and of actin-remodeling proteins as cofilin and transgelin were 
observed after a proteomic quantification of human normal chondrocytes [53]; moreover, higher 
accumulation of nuclear actin is considered a marker of cellular senescence [53]. These 
accumulating evidence led us to consider these proteins as OA progression- and senescence-related 
proteins. Recently, a paper studying the proteomic profile of human normal chondrocyte by two-
dimensional electrophoresis analysis reported an abundant icrease of intermediate filament vimentin 
after stimulus of the cells with IL-1β [54]. Similarly, in our work we observed an increase of 
vimentin protein fragments in IL-1β-stimulated cells even, if in a not significant manner. VA692 
was able to reduce the amount of these proteins in chondrocytes cell line subjected to a cytokine 
damaging stimulus; so we hypothesize that VA692 could have a role in restoring cytoskeleton 
organization following stress conditions.  
HSP90 have been found involved in many processes contributing to age-related changes in cartilage 
ECM as MMPs expression, NO synthesis and production of COX-2 [55]. Data from literature 
described altered protein levels of HSP90B in OA chondrocytes; indeed, results from proteomic 
analysis showed increased HSP90B and GRP78 proteins in diseased cells [56]. In addition, an in 
vitro study of proteome strategy in T/C-28a4 cell line demonstrated the increase of HSP70 and 
HSP90 following a negative stress [57]; this result confirm the up-regulation of HSP10 in T/C-28a2 
cell line induced by the stimulus of IL-1β in our study. On the other hand, a down-regulation of 
HSP90 (A and B), HSP7C as well as of some proteins involved in glycolysis process were observed 
when our cells were pharmacologically treated with VA692. Indeed, the increased expression of 
these proteins seems to be related to the impaired glucose metabolism that occur in chondrocytes 
under stress conditions or during OA cartilage degradation [56]. Moreover, HSP90 has also been 
found to accelerate NO synthesis and apoptosis in OA pathogenesis and after IL-1β stimulus 
[56,58]. These findings highlight the role of the studied chaperones proteins in mediating cellular 
 
 
responses under stress conditions, and in particular we demonstrated the ability of VA692 to 
modulate them speculating its possible role in regulation of chondrocyte metabolism. 
Another result obtained by the proteomic analysis was the up-regulation of Cu-Zn SOD or SOD-1 
in IL-1β-stimulated chondrocytes. Cu-Zn SOD is the intracellular isoform of SOD principally found 
in the cytosol and in the nucleus of the cells, but also in the mitochondrial intermembrane space, 
where exerts its mitochondrial functions against oxidative stress [58]. Little is known about the 
modulation of Cu-Zn SOD in chondrocyte cultures and, to our knowledge, this is the first report 
observing its regulation in IL-1β-stimulated chondrocyte cell line at proteome level. An in vitro 
experiment on human normal chondrocyte cultures observed the modulation of IL-1β in increasing 
SOD-2 protein [54]; these data support our results demonstrating the effect of the pro-inflammatory 
cytokine on SOD family, despite a different type of cells have been employed. 
After the treatment with the new compound VA692, we found a higher expression of SOD-1. These 
findings suggest that the anti-oxidant defense increased to counteract the increased ROS levels 
produced following a cytokine stimulus and underline the ability of our pharmacological treatment. 
This result, taken together with our previous described data, confirms the role of VA692 in T/C-
28a2 anti-oxidant system.  
CALM, CALU, RCN, CALR and CALD1 are multifunctional Ca
2+
 transducer and Ca
2+
-sensor 
proteins and this is the basis of the competence of these proteins to transduce Ca
2+
 signals and 
mediates many of the regulatory effects of Ca
2+ 
. These proteins are expressed in all eukaryotic 
cells, participating in signaling pathways and regulating many crucial physiological processes [59]. 
An in vitro study on human fibroblasts affirmed the strong interaction between IL-1 and calcium-
binding proteins, resulting in generation of calcium signals; this link was considered essential for 
activation of signaling pathways including the production of matrix protein degrading proteases 
[60]. This could explain and support our results about the up-regulation of proteins calmodulin and 
reticulocalbins following IL-1β stimulus; however the studies are not comparable due to the 
different used cell types, and more, the role of calcium-binding proteins in chondrocytes is not well 
 
 
elucidated [61]. Then, we observed a significant up-regulation of CALM, CALU, RCN, CALR and 
CALD1 after the treatment of the T/C-28a2 cell line with VA692. The raised levels of these 
proteins regulators of Ca
+
 could be related to the increase of their activity as a consequence of IL-1β 
availability, responsible for the increase in calcium signal [60], which is maintained also in the 
presence of the drug. These data lead us to speculate regarding the putative role of VA692 in 
regulating calcium signal under stress conditions. 
Interestingly, some proteins involved in osteblast differentiation, such as CLH1 and FSN, were also 
identified in our proteomic analysis. Osteoclasts are multi-nucleated cells and their physiological 
function is to degrade bone matrix; this bone-resorbing activity is essential for controlling bone 
development and turnover. Osteoclasts differentiation is regulated by osteoblasts for both bone 
mineralization and osteoclast function, by the activation of receptor activator of nuclear factor B 
(RANK) [62]. Clathrin plays a key role in many different signaling pathways, as RANK, mediating 
a broad range of cellular processes from embryonic development, cell homeostasis and metabolism 
and osteoaclastogenesis [63]. No evidence is available concerning the implication of these proteins 
in OA; however, an analysis performed on intracellular proteome of OA chondrocytes reported a 
significant decrease of periostin, known to be associated to tissue mineralization, after IL-1β 
stimulus; the authors hypothesized that the altered synthesis of that protein could be explain the 
pathological events that occur in OA chondrocytes as cell hypertrophy  and matrix mineralization 
[64]; however, this report is not comparable with our study. Our results didn’t show any significant 
modulation of CLH and FSN in IL-1β-stimulated T/C-28a2, on the other hand we observed a 
significant reduction of those proteins after treatment with VA692. Although its just a preliminary 
result, the modulation induced by our compound of interest could hypothesize its role in reducing 
bone mineralization; additional studies are needed to better elucidate this aspect. 
In conclusion, on the basis of our results, the novel compound VA692 has more beneficial effect 
compared to celecoxib on the modulation of the inflammatory response and the redox system. The 
proteomic analysis performed in this work provides new information about the effect of VA692 on 
 
 
human T/C-28a2 cell line intracellular proteome, demonstrating the usefulness of this approach in 
the identification and quantifications of several proteins. Some of them had not previously reported 
to be produced by chondrocytes, for instance proteins involved in calcium metabolism. However, 
the study presents a limitation due to the lack of additional techniques to apply on protein extracts, 
as western blot or qRT-PCR, in order to confirm and support the modulation observed in 
chondrocytes proteome; indeed, candidate proteins need to be validated by an orthogonal technique 
before their biological roles are pursued. The results obtained in T/C-28a2 cell line encourage to 
carry on the experiments evaluating the proteomic profile also in OA chondrocyte primary cultures 
following VA692-treatment. These points represent the fundamental for future studies.  
Further in vitro and in vivo experiments are necessary to confirm if VA692 could present any 
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Figure 1: Chemical structures of celecoxib, 1,5-diarylpyrrole-3-alkoxyethyl ethers (1), VA694 (2), 
and VA692 (3). 
Figure 2. Inflammatory modulation. Genetic expression levels of COX-2, IL-1β, IL-6 and IL-8 
evaluated in T/C-28a2 (A), and in HAC (Human articular chondrocytes) (B). The gene expression 
was referenced to the ratio of the value of interest and basal condition; the value of basal conditions 
was reported equal to 1. (C) Total amount of PGE2 (pg/ml) detected in the culture medium of T/C-
28a2 and in HAC.  The cells were incubated in presence of celecoxib (Cel) and VA692 at 1µM with 
a 2 hour of pre-treatment with IL-1β (5ng/ml). Data were expressed as mean ± SD of triplicate 
values. °° p<0.01, °°° p<0.001 IL-1β versus basal condition (Basal, cells without treatment). * 
p<0.05, ** p<0.01, ***p<0.001 celecoxib or VA692 treatment versus IL-1β. Ba. = basal condition. 
Figure 3. ROS production/response and Apoptotis detection. (A) The production levels of 
mitochondrial superoxide anion were analyzed using MitoSox Red staining. (B-C) Expression 
levels of SOD-2 and CAT in T/C-28a2 (B) and in HAC (Human articular chondrocytes) (C). The 
gene expression and the production of superoxide anion were referenced to the ratio of the value of 
interest and basal condition; the value of basal conditions was reported equal to 1. (D) Western blot 
of SOD-2 in T/C28a2; a representative immunoblotting image and densitometric analysis of SOD-2 
protein levels. The ratio of protein level was referenced to the ratio of the value of interest and basal 
condition. The value of basal conditions was reported equal to 1. (E) Apoptosis measured with 
Annexin-V-FITC assay: data were expressed as percentage of positive cells for Annexin-V and 
propidium iodide (PI). The ratio of apoptosis was referenced to the ratio of the value of interest and 
basal condition. The value of basal conditions was reported equal to 1.  
Cells were incubated in presence of celecoxib (Cel) and VA692 at 1µM with a 2 hour of pre-
treatment with IL-1β (5ng/ml). Data were expressed as mean ± SD of triplicate values. ° p<0.05, °° 
p<0.01, °°° p<0.001 IL-1β versus basal condition (Basal, cells without treatment). * p<0.05, ** 
p<0.01, ***p<0.001 IL-1β celecoxib or VA692 treatment versus IL-1β. 
 
 
Figure 4. Data mining for proteomic analysis performed in proteome of T/C-28a2 cell line treated 
for 48 hours with celecoxib and VA692 (1µM) in presence of IL-1β (2 hours of pre-treatment) (5 
ng/ml), according to Gene Ontology annotation. Component pie charts indicating the biological 
processes in which the identified proteins are involved (A) and their cellular localization (B). Venn 
diagram represents proteins exclusively or commonly modulated by VA692 and IL-1β (C). 
Figure 5. STRING analysis of the 53 down-regulated proteins highlighted cell differentiation (red 
nodes) as the main altered process in VA692 treated cells (A). In panel B proteins involved in 
osteoblast differentiation are marked in red.  
String analysis of the 70 up-regulated proteins highlighted protein organization (red nodes) as the 
main altered process in VA692 treated cells (C). In panel D proteins involved in protein translation 



















Table 1. List of primers used for qRT-PCR. 






















































50.24 62.7 P14618 Pyruvate kinase isozymes M1/M2 KPYM 29 0.5916 0.0004 
41.79 26.6 P49327 Fatty acid synthase FAS 20 0.7047 0.0348 
36.26 69 P07355 Annexin A2 ANX2  29 0.5248 0.0011 
35.26 72.2 P04406 Glyceraldehyde-3-phosphate dehydrogenase GAPD  32 0.4875 0.0038 
33.39 70.8 P06748 Nucleophosmin NPM 32 2.576 0.0232 
32.2 55.9 P05787 Keratin. type II cytoskeletal 8 CYK8  25 0.4875 0.0006 
31.21 49.4 Q5VTE0 Putative elongation factor 1-alpha-like 3 EF1A3 18 0.5808 0.0276 
24.01 53.7 Q8NC51 Plasminogen activator inhibitor 1 RNA-binding protein PAIRB 15 1.7378 0.0023 
23.95 80.5 P63241 Eukaryotic translation initiation factor 5A-1 IF5A1 20 3.5318 0.0084 
22.31 53.7 P05783 Keratin. type I cytoskeletal 18 CYK18  14 0.4246 0.002 
18.26 83.9 P62158 Calmodulin CALM 16 3.6219 0.0037 
26.36 64.8 P09493 Tropomyosin alpha-1 chain TMSA  17 2.0137 0.0453 
16.97 61 Q07021 Complement component 1 Q subcomponent-binding protein mitochondrial C1QBP 15 2.3121 0.0204 
15.05 42.9 Q14257 Reticulocalbin-2 RCN2 9 3.6983 0.0016 
14.85 52.5 P51858 Hepatoma-derived growth factor HDGF 7 2.421 0.0104 
14.63 36.7 Q92945 Far upstream element-binding protein 2 FUBP2  9 1.4588 0.0302 
14.24 44.6 P31948 Stress-induced-phosphoprotein 1 STIP1 7 2.421 0.0073 
14 57.7 Q07955 Serine/arginine-rich splicing factor 1 SRSF1 8 2.0701 0.0372 
13.78 43.1 P04083 Annexin A1 ANX1  8 0.5861 0.0054 
12.91 23.5 P14314 Glucosidase 2 subunit beta GLU2B 6 1.977 0.0436 
12 53.6 Q00688 Peptidyl-prolyl cis-trans isomerase FKBP3 FKBP3 5 1.6293 0.0554 
11.3 48.1 P00441 Superoxide dismutase [Cu-Zn] SODC 6 5.3456 0.0142 
11.26 46.2 Q01105 Protein SET SET 10 2.7797 0.016 
11.06 63.1 P16949 Stathmin STMN1 5 1.977 0.0182 
10.41 48.8 Q96C19 EF-hand domain-containing protein D2 EFHD2  7 2.208 0.0494 
10.1 66.7 P61604 10 kDa heat shock protein mitochondrial CH10 6 2.3121 0.0357 
10.06 70.7 Q04760 Lactoylglutathione lyase GLO1  5 2.7542 0.0363 
 
 
10.05 54.9 Q9NX55 Huntingtin-interacting protein K HYPK  5 3.0761 0.0193 
10 49.5 P10599 Thioredoxin TXN  7 2.2284 0.0467 
9.13 44.8 Q96D15 Reticulocalbin-3 RCN3 5 3.46 0.0331 
8.66 31 Q14847 LIM and SH3 domain protein 1 LASP1  5 2.1878 0.0352 
8.4 68.5 O75347 Tubulin-specific chaperone A TBCA  4 3.1623 0.0399 
8.38 32.3 P54727 UV excision repair protein RAD23 homolog B RAD23B  4 1.888 0.028 
8 71.3 P07108 Acyl-CoA-binding protein RAD23B  6 259648 0.0621 
 
  
# Protein accession number according to Swiss-Prot database. $Average iTRAQ ratio representing the relative protein abundance in IL-1β cells vs basal conditions. quantified by 




























Table 3. Celecoxib-modulated proteins in T/C-28a2 proteome 






46.45 64.2 P08670 Vimentin VIME 41 1.5136 0.0158 
35.26 72.2 P04406 Glyceraldehyde-3-phosphate dehydrogenase G3P 32 1.9409 0.007 
31.21 49.4 Q5VTE0 Putative elongation factor 1-alpha-like 3 EF1A3 18 1.6293 0.0494 
21.35 51.5 P07195 L-lactate dehydrogenase B chain LDHB 13 2.1677 0.0074 
14.39 64.2 Q02878 60S ribosomal protein L6 RL6 8 1.977 0.0486 
6.03 24.2 P09496 Clathrin light chain A CLCA 7 0.8166 0.0096 







# Protein accession number according to Swiss-Prot database. $Average iTRAQ ratio representing the relative protein abundance in celecoxib + IL-1β cells vs basal conditions. 





















Table 4. VA692-modulated proteins in T/C-28a2 proteome 
 
Score % Cov Accession
#






120.75 53.8 P35579 Myosin-9 MYH9 74 0.2999 0 
84.46 51.4 Q09666 Neuroblast differentiation-associated protein AHNAK AHNK 44 1.7504 0 
73.81 33.6 P21333 Filamin-A FLNA 39 0.50927 0 
68.67 61.6 P12814 Alpha-actinin-1 ACTN1 49 0.5506 0.0083 
52.45 72.1 P11142 Heat shock cognate 71 kDa protein HSP7C 33 0.51067 0.047 
51.67 58.3 P19338 Nucleolin NUCL 29 4.1515 0 
50.52 62.6 P07900 Heat shock protein HSP 90-alpha HS90A 28 0.31137 0.0215 
50.24 62.7 P14618 Pyruvate kinase isozymes M1/M2 KPYM 29 0.35685 0.0001 
53.95 32.2 O75369 Filamin-B FLNB 29 0.4193 0.0016 
46.45 64.2 P08670 Vimentin VIME 41 0.7178 0.0136 
41.79 26.6 P49327 Fatty acid synthase FAS 20 0.3392 0 
38.27 93.8 P16401 Histone H1.5 H15 18 9.798 0.0013 
37.76 44.6 P13639 Elongation factor 2 EF2 19 0.4895 0.0034 
36.12 23.9 Q15149 Plectin PLEC 20 0.3621 0.0009 
33.39 70.8 P06748 Nucleophosmin NPM 32 2.531 0.0004 
31.21 49.4 Q5VTE0 Putative elongation factor 1-alpha-like 3 EF1A3 18 0.486 0.0205 
31.04 89.7 P62937 Peptidyl-prolyl cis-trans isomerase A PPIA 32 3.4956 0.0131 
27.78 75.1 P60174 Triosephosphate isomerase TPIS 18 1.7996 0.0222 
27.6 46 P12956 X-ray repair cross-complementing protein 6 XRCC6 14 0.486 0.0093 
27.47 36.1 P27816 Microtubule-associated protein 4 MAP4 14 1.757 0.0044 
27.4 69.4 P62258 14-3-3 protein epsilon 1433E 16 2.8063 0.0089 
27 86.8 P23528 Cofilin-1 COF1 16 2.4281 0.0114 
24.98 63.3 P09429 High mobility group protein B1 HMGB1 15 5.0249 0.0002 
24.95 34.2 P46940 Ras GTPase-activating-like protein IQGAP1 IQGA1 11 0.2938 0.0002 
24.21 95.2 P80723 Brain acid soluble protein 1 BASP1 11 3.7487 0.0001 
24.01 53.7 Q8NC51 Plasminogen activator inhibitor 1 RNA-binding protein PAIRB 15 2.5086 0.0001 
34.77 90.6 P16403 Histone H1.2 H12 21 2.5784 0.0066 
23.95 80.5 P63241 Eukaryotic translation initiation factor 5A-1 IF5A1 20 1.6417 0.0082 
 
 
23.13 25.3 Q00610 Clathrin heavy chain 1 CLH1 12 0.4771 0.0032 
23.01 33.7 P07237 Protein disulfide-isomerase PDIA1 15 1.8096 0.0171 
22.42 23.6 Q01082 Spectrin beta chain. brain 1 SPTB2 11 0.2114 0.0051 
22.07 91.4 P07737 Profilin-1 PROF1 16 2.0607 0.0057 
21.88 28.2 P22314 Ubiquitin-like modifier-activating enzyme 1 UBA1 15 0.367 0.0082 
21.78 18.1 P78527 DNA-dependent protein kinase catalytic subunit PRKDC 10 0.3464 0.0369 
48.31 59.8 P08238 Heat shock protein HSP 90-beta HS90B 30 0.3981 0.0096 
21.72 34.7 Q7KZF4 Staphylococcal nuclease domain-containing protein 1 SND1 12 0.4742 0.0055 
21.28 53 P27797 Calreticulin CALR 12 4.953 0 
20.24 45.4 P07910 Heterogeneous nuclear ribonucleoproteins C1/C2 HNRPC 12 2.3478 0.0026 
20.2 26.4 P55060 Exportin-2 XPO2 11 0.3311 0.0131 
20.2 26.4 P55060 Exportin-2 XPO2 11 0.302 0.001 
19.76 34.7 Q00839 Heterogeneous nuclear ribonucleoprotein U HNRPU 11 0.5495 0.0204 
26.64 50.8 P09651 Heterogeneous nuclear ribonucleoprotein A1 ROA1 19 2.2909 0.038 
18.26 83.9 P62158 Calmodulin CALM 16 2.647 0.0008 
18.18 80.6 P62805 Histone H4 H4 19 1.6219 0.0224 
17.8 66 O43852 Calumenin CALU 10 3.396 0.0017 
16.97 61 Q07021 Complement component 1 Q subcomponent-binding protein. mitochondrial C1QBP 15 2.5645 0.0417 
16.98 15.5 O75643 U5 small nuclear ribonucleoprotein 200 kDa helicase U520 8 0.3076 0.0009 
16.41 32.5 Q08211 ATP-dependent RNA helicase A DHX9 11 0.3945 0.0243 
25.87 30.9 P35580 Myosin-10 MYH10 13 0.4325 0.0034 
16.1 39.7 P48643 T-complex protein 1 subunit epsilon TCPE 8 0.4702 0.0177 
15.97 39.9 P13010 X-ray repair cross-complementing protein 5 XRCC5 8 0.497 0.027 
15.51 38.6 Q14103 Heterogeneous nuclear ribonucleoprotein D0 HNRPD 7 4.5823 0.0051 
15.4 18.5 P41252 Isoleucyl-tRNA synthetase. cytoplasmic SYIC 9 0.3048 0.0475 
15.05 42.9 Q14257 Reticulocalbin-2 RCN2 9 2.5351 0.0004 
14.87 33 P39023 60S ribosomal protein L3 RL3 8 0.5598 0.0252 
14.85 52.5 P51858 Hepatoma-derived growth factor HDGF 7 2.0137 0.0102 
14.41 22.8 Q92841 Probable ATP-dependent RNA helicase DDX17 DDX17 7 0.5058 0.0291 
14.24 44.6 P31948 Stress-induced-phosphoprotein 1 STIP1 7 2.3893 0.0044 
14.1 20.2 Q04637 Eukaryotic translation initiation factor 4 gamma 1 IF4G1 7 0.4152 0.0393 
 
 
14.06 27.2 Q14697 Neutral alpha-glucosidase AB GANAB 7 0.5445 0.0315 
14 57.7 Q07955 Serine/arginine-rich splicing factor 1 SRSF1 8 1.8707 0.0255 
13.94 56 P24534 Elongation factor 1-beta EF1B 8 3.2463 0.0267 
13.93 24.2 P18206 Vinculin VINC 8 0.4742 0.0211 
13.91 38.1 Q05682 Caldesmon CALD1 9 2.466 0.0018 
12.95 15.3 Q14204 Cytoplasmic dynein 1 heavy chain 1 DYHC1 6 0.302 0.0021 
12.91 23.5 P14314 Glucosidase 2 subunit beta GLU2B 6 2.321 0.0059 
12.67 63.6 O75822 Eukaryotic translation initiation factor 3 subunit J EIF3J 7 2.5062 0.0058 
12.44 49.7 P39019 40S ribosomal protein S19 RS19 7 2.5923 0.0187 
13.83 41.3 O75475 PC4 and SFRS1-interacting protein PSIP1 7 3.0523 0.0092 
12 53.6 Q00688 Peptidyl-prolyl cis-trans isomerase FKBP3 FKBP3 5 2.4677 0.0007 
11.87 41.4 P20042 Eukaryotic translation initiation factor 2 subunit 2 IF2B 7 2.0953 0.0243 
11.76 15.2 Q14974 Importin subunit beta-1 IMB1 7 0.5058 0.0119 
14.72 26 P14625 Endoplasmin ENPL 9 0.49178 0.0797 
11.53 33.6 O43175 D-3-phosphoglycerate dehydrogenase SERA 6 0.54 0.0797 
25.53 51.8 P06753 Tropomyosin alpha-3 chain TPM3 16 2.7351 0.0549 
11.55 50.3 P05455 Lupus La protein LA 5 1.6444 0.07 
11.3 48.1 P00441 Superoxide dismutase [Cu-Zn] SODC 6 3.0761 0.0051 
11.26 46.2 Q01105 Protein SET SET 10 2.1178 0.0125 
11.06 63.1 P16949 Stathmin STMN1 5 2.6823 0.0009 
11.05 30.2 Q14978 Nucleolar and coiled-body phosphoprotein 1 NOLC1 5 2.3137 0.045 
10.56 27.5 P25705 ATP synthase subunit alpha. mitochondrial ATPA 6 0.413 0.0201 
10.44 20.6 P33991 DNA replication licensing factor MCM4 MCM4 5 0.4125 0.0441 
10.41 49 P05141 ADP/ATP translocase 2 ADT2 6 0.381 0.0273 
30.49 91.4 P16402 Histone H1.3 H13 18 3.1675 0.0048 
10.18 52.4 P62841 40S ribosomal protein S15 RS15 5 2.3271 0.1081 
10.13 37 P20810 Calpastatin ICAL 5 1.945 0.0164 
10.2 23 O43776 Asparaginyl-tRNA synthetase. cytoplasmic SYNC 5 0.302 0.0214 
10.1 66.7 P61604 10 kDa heat shock protein. mitochondrial CH10 6 2.546 0.0104 
10.01 43.3 P53999 Activated RNA polymerase II transcriptional coactivator p15 TCP4 5 2.3335 0.0244 
10.01 43.3 P53999 Activated RNA polymerase II transcriptional coactivator p15 TCP4 5 2.9376 0.0144 
 
 
10 32.1 Q13242 Serine/arginine-rich splicing factor 9 SRSF9 5 2.3959 0.0434 
16.14 63.6 P26583 High mobility group protein B2 HMGB2 10 2.9589 0.008 
9.85 40.4 P63244 Guanine nucleotide-binding protein subunit beta-2-like 1 GBLP 5 0.5395 0.0298 
9.76 39 Q15293 Reticulocalbin-1 RCN1 5 2.508 0.0036 
9.52 17.3 O14980 Exportin-1 XPO1 5 0.332 0.0554 
9.26 27.8 P50991 T-complex protein 1 subunit delta TCPD 5 0.4966 0.0267 
9.24 48.9 Q8WXX5 DnaJ homolog subfamily C member 9 DNJC9 5 1.9588 0.0332 
9.2 70.5 P25398 40S ribosomal protein S12 RS12 5 3.2509 0.0308 
9.17 17.8 Q13428 Treacle protein TCOF 5 2.5823 0.0396 
9.13 44.8 Q96D15 Reticulocalbin-3 RCN3 5 2.1878 0.0108 
9.07 20.2 Q9Y490 Talin-1 TLN1 4 0.492 0.0417 
8.96 58.3 P62750 60S ribosomal protein L23a RL23A 5 1.393 0.0119 
8.76 37.5 Q02543 60S ribosomal protein L18a RL18A 4 0.52 0.0343 
8.76 63.7 P09382 Galectin-1 LEG1 6 2.0701 0.0281 
8.41 26.9 P06744 Glucose-6-phosphate isomerase G6PI 4 0.3105 0.0093 
8.4 36 P50502 Hsc70-interacting protein F10A1 5 2.6303 0.0305 
8.1 23.2 Q9NTJ3 Structural maintenance of chromosomes protein 4 SMC4 4 0.2148 0.045 
8.15 17.9 Q9Y5B9 FACT complex subunit SPT16 SP16H 4 0.302 0.0376 
8.05 55.2 P62851 40S ribosomal protein S25 RS25 4 3.5645 0.037 
8.01 30.1 Q00059 Transcription factor A. mitochondrial TFAM 4 2.5119 0.0336 
8 71.3 P07108 Acyl-CoA-binding protein RAD23B  6 2.1893 0.037 
9.52 42.5 P00338 L-lactate dehydrogenase A chain LDHA 7 0.3873 0.0439 
7.6 22.2 Q15942 Zyxin ZYX 4 2.7797 0.0103 
9.27 30.4 Q99729 Heterogeneous nuclear ribonucleoprotein A/B ROAA 5 2.2491 0.0222 
6.84 30.1 P29966 Myristoylated alanine-rich C-kinase substrate MARCS 3 1.8365 0.0699 
33.42 93.6 P10412 Histone H1.4 H14 19 5.929 0.0187 
6.05 25.5 P49321 Nuclear autoantigenic sperm protein NASP 3 1.9409 0.0465 
5.86 11.4 P05023 Sodium/potassium-transporting ATPase subunit alpha-1 AT1A1 3 0.6194 0.033 
5.54 28.3 P23588 Eukaryotic translation initiation factor 4B IF4B 4 1.977 0.0591 
5.15 71.5 Q15121 Astrocytic phosphoprotein PEA-15 PEA15 3 2.466 0.0297 
5.04 36.5 Q13442 28 kDa heat- and acid-stable phosphoprotein HAP28 4 2.355 0.0459 
 
 
4.91 47.3 P00492 Hypoxanthine-guanine phosphoribosyltransferase HPRT 2 0.1096 0.0307 
4.53 67.8 P05204 Non-histone chromosomal protein HMG-17 HMGN2 2 8.2462 0.0134 
6.03 46.3 P42766 60S ribosomal protein L35 RL35 4 2.5119 0.0258 
4 20.5 Q8N163 Protein KIAA1967 K1967 2 0.0288 0.033 
 
# Protein accession number according to Swiss-Prot database. $Average iTRAQ ratio representing the relative protein abundance in IL-1β cells vs basal conditions. quantified by 
ProteinPilot 3.0 software. A p value ≤0.05 was accepted.
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